General Information of Drug (ID: DMF1VS9)

Drug Name
AV-370 Drug Info
Synonyms Anti-FGF3 receptor antibody (cancer), AVEO Pharmaceuticals
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMF1VS9

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pemigatinib DM819JF Cholangiocarcinoma 2C12.10 Approved [2]
Trapidil DMY67U8 Acute coronary syndrome BA41 Phase 4 [3]
E-3810 DM42PFT Solid tumour/cancer 2A00-2F9Z Phase 3 [4]
TKI258 DMYLT67 Renal cell carcinoma 2C90 Phase 3 [5]
BMS-582664 DMDAN8H Hepatocellular carcinoma 2C12.02 Phase 3 [5]
Debio 1347 DMZW50O Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
B-701 DMOMDA4 Bladder cancer 2C94 Phase 2 [7]
Recifercept DML8N3Y Achondroplasia LD24.00 Phase 2 [8]
MK-2461 DM21WBH Alzheimer disease 8A20 Phase 1/2 [9]
AEE-788 DMEOS5K Solid tumour/cancer 2A00-2F9Z Phase 1/2 [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fibroblast growth factor receptor 3 (FGFR3) TTST7KB FGFR3_HUMAN Not Available [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1810).
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
4 E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
5 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia. PLoS One. 2020 Dec 28;15(12):e0244368.
9 MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.